Pharmacological inhibition of Src family kinases attenuates hyperuricemic nephropathy

Area of Science:

• Nephrology
• Molecular Biology
• Pharmacology

Background:

• Hyperuricemia is a significant risk factor for chronic kidney disease (CKD) and promotes renal fibrosis.
• Understanding the molecular mechanisms underlying hyperuricemic nephropathy (HN) is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the therapeutic effect of Src family kinase (SFK) inhibition on hyperuricemic nephropathy (HN) in a rat model.
• To elucidate the underlying mechanisms by which SFK inhibition impacts renal fibrosis and dysfunction.

Main Methods:

• A rat model of HN was established using adenine and potassium oxonate.
• The selective SFK inhibitor PP1 was administered to assess its effects on renal pathology, function, and signaling pathways.
• Key markers of renal fibrosis, inflammation, and uric acid metabolism were analyzed.

Main Results:

• PP1 administration attenuated renal dysfunction, reduced albuminuria, and inhibited glomerular sclerosis and interstitial fibrosis in HN rats.
• PP1 treatment suppressed the activation of TGF-β1/Smad3, STAT3, ERK1/2, and NF-κB signaling pathways.
• SFK inhibition also decreased serum uric acid levels and xanthine oxidase activity, indicating reduced uric acid production.

Conclusions:

• Src family kinase inhibition effectively mitigates the development of hyperuricemic nephropathy.
• The protective effects are mediated through the suppression of pro-fibrotic signaling pathways, inflammation, and uric acid production.
• Targeting SFKs presents a promising therapeutic strategy for managing hyperuricemic nephropathy and related kidney diseases.